Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, open-label, three-part adaptive design, crossover study of AQST-109

Next Previous
X
Search
Trial Profile

Randomized, open-label, three-part adaptive design, crossover study of AQST-109

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AQST 109 (Primary) ; AQST 109 (Primary)
  • Indications Anaphylaxis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms EPIPHAST; EPIPHAST I
  • Sponsors Aquestive Therapeutics

    • Most Recent Events

    • 15 Feb 2024 According to an Aquestive Therapeutics media release, positive pharmacokinetic (PK) and pharmacodynamic (PD) data from this study will be will be presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting, which will take place February 23-26 in Washington, D.C.
    • 07 Mar 2023 According to an Aquestive Therapeutics media release, data from this trial presented at the American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting held in November 2022
    • 27 Feb 2023 Results presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top